BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31158785)

  • 21. Evolving Outsourcing Landscape in Pharma R&D: Different Collaborative Models and Factors To Consider When Choosing a Contract Research Organization.
    DeCorte BL
    J Med Chem; 2020 Oct; 63(20):11362-11367. PubMed ID: 32479727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Future trends in outsourcing: a summary of the Bioanalysis Zone Survey.
    Craddock A; Nadarajah S
    Bioanalysis; 2017 Aug; 9(15):1127-1129. PubMed ID: 28766363
    [No Abstract]   [Full Text] [Related]  

  • 23. Outsourcing lead optimization: constant change is here to stay.
    Clark DE
    Drug Discov Today; 2007 Jan; 12(1-2):62-70. PubMed ID: 17198974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outsourcing drug work. Pharmaceuticals ship R&D and clinical trials to India.
    Sinha G
    Sci Am; 2004 Aug; 291(2):24-5. PubMed ID: 15298112
    [No Abstract]   [Full Text] [Related]  

  • 25. Just how good an investment is the biopharmaceutical sector?
    Thakor RT; Anaya N; Zhang Y; Vilanilam C; Siah KW; Wong CH; Lo AW
    Nat Biotechnol; 2017 Dec; 35(12):1149-1157. PubMed ID: 29220034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Scale, scope, and spillovers: the determinants of research productivity in drug discovery.
    Henderson R; Cockburn I
    Rand J Econ; 1996; 27(1):32-59. PubMed ID: 10160535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outsourcing for product success and restful nights.
    Hale D
    Med Device Technol; 2008; 19(7):32, 34-5. PubMed ID: 19133626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conference report: a hitchhiker's guide to outsourcing ADME studies: the inside of outsourcing.
    Pritchard JF; Anderson SR; Breuckner C; Premkumar ND; Polli JW
    Bioanalysis; 2013 Feb; 5(4):403-5. PubMed ID: 23414372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global outsourcing.
    Garofolo W; Garofolo F
    Bioanalysis; 2010 Feb; 2(2):149-52. PubMed ID: 21083294
    [No Abstract]   [Full Text] [Related]  

  • 30. Globalization in the pharmaceutical industry, Part II.
    Casadio Tarabusi C; Vickery G
    Int J Health Serv; 1998; 28(2):281-303. PubMed ID: 9595345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increase in R&D openness to tackle disease in the developing world.
    Parks L
    Future Med Chem; 2012 Dec; 4(18):2237. PubMed ID: 23234547
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmaceutical R&D performance by firm size: approval success rates and economic returns.
    DiMasi JA
    Am J Ther; 2014; 21(1):26-34. PubMed ID: 23344103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The inherent risks associated with newly traded biopharmaceutical firms.
    Williams DR; Spaulding TJ
    Drug Discov Today; 2018 Sep; 23(9):1680-1688. PubMed ID: 29936246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances.
    Danzon PM; Nicholson S; Pereira NS
    J Health Econ; 2005 Mar; 24(2):317-39. PubMed ID: 15721048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outsourcing lead optimisation--the quiet revolution.
    Clark DE; Newton CG
    Drug Discov Today; 2004 Jun; 9(11):492-500. PubMed ID: 15149625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of product subsidies on R&D investment for new energy vehicle firms: Considering quality preference of the early adopter group.
    Meng W; Wang Y; Li Y; Huang B
    PLoS One; 2020; 15(7):e0236626. PubMed ID: 32735570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The promise of the East: India and China as R&D options.
    Goodall S; Janssens B; Wagner K; Wong J; Woods W; Yeh M
    Nat Biotechnol; 2006 Sep; 24(9):1061-4. PubMed ID: 17061321
    [No Abstract]   [Full Text] [Related]  

  • 38. Outsourcing is in.
    Landhuis E
    Nature; 2018 Apr; 556(7700):263-265. PubMed ID: 29643487
    [No Abstract]   [Full Text] [Related]  

  • 39. The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.
    Cockburn I; Long G
    Expert Opin Ther Pat; 2015 Jul; 25(7):739-42. PubMed ID: 25927945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Returns on research and development for 1990s new drug introductions.
    Grabowski H; Vernon J; DiMasi JA
    Pharmacoeconomics; 2002; 20 Suppl 3():11-29. PubMed ID: 12457422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.